WuXi Biologics wins ABL Bio contract for bispecific antibodies

By Flora Southey

- Last updated on GMT

(Image: Getty/Ruskpp)
(Image: Getty/Ruskpp)

Related tags CDMO Wuxi biologics South korea China

South Korean biotech ABL Bio has selected WuXi Biologics to develop and manufacture up to eight bispecific antibodies for the clinic.

ABL Bio Corporation’s bispecific antibodies, which bind two different epitopes either on the same or different targets, are being developed for immune-oncology and neurodegenerative diseases.

WuXi Biologics and ABL Bio’s agreement will see the Chinese contract development and manufacturing organisation (CDMO) prepare up to eight bispecific antibodies for clinical trials.

Candidates will be selected from both ABL Bio’s pipeline and collaboration programmes​ between ABL Bio and I-Mab Biopharma.

“The partnership with WuXi Biologics is an important strategy for growing our internal and external programmes of next-generation…biologics, such as [the] bispecific antibody,” ​said ABL Bio CEO Sang Hoon Lee in a statement.

For WuXi Biologics, the exclusive partnership marks its first in South Korea. The CDMO is expanding internationally, with an estimated capacity of 220,000 litres planned across China, Ireland​, Singapore​, and the US​ by 2021.

Earlier this month, the firm broke ground​ on its eight drug substance manufacturing facility – located in China’s Hebei province – and announced plans​ to build a discovery, development and manufacturing site in the Fengxian district of Shanghai.

Related news

Show more

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us

Products

View more

Webinars